KALVISTA PHARMACEUTICALS INC (KALV) Earnings History & Surprises
NASDAQ:KALV • US4834971032
18.44 USD
+1.14 (+6.59%)
At close: Mar 10, 2026
17.0165 USD
-1.42 (-7.72%)
After Hours: 3/10/2026, 8:00:03 PM
Past quarterly earnings results for KALVISTA PHARMACEUTICALS INC (KALV), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Release DateMar 17, 2026
PeriodQ3 / 2026
EPS Estimate-$0.77
Revenue Estimate13.341M
Last Reported
Release DateJan 8, 2026
PeriodQ2 / 2026
EPS Reported-$0.92
EPS Surprise 13.27%
Revenue Surprise 86.21%
Beat Rate
25%
EPS and Revenuebeats vs estimates
Quarterly Earnings Results
EPS & Revenue History (USD)
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | -0.92 | -1.06 | 13.27% | -1.10% | 13.692M | 7.353M | 86.21% | - |
| Q1 2026 | -1.12 | -0.55 | -102.71% | -28.74% | 1.426M | 35.587M | -95.99% | - |
| Q4 2025 | -0.99 | -0.48 | -106.51% | 2.94% | - | - | ||
| Q3 2025 | -0.78 | -0.89 | 12.51% | 7.14% | - | - | ||
| Q2 2025 | -0.91 | -0.93 | 1.74% | -13.75% | - | - | ||
| Q1 2025 | -0.87 | -0.93 | 6.68% | -17.57% | - | - | ||
| Q4 2024 | -1.02 | -0.75 | -36.67% | -32.47% | - | - | ||
| Q3 2024 | -0.84 | -0.78 | -7.35% | -12.00% | - | - | ||
| Q2 2024 | -0.80 | -0.80 | 0.27% | 11.11% | - | - | ||
| Q1 2024 | -0.74 | -0.88 | 15.48% | 21.28% | - | - | ||
| Q4 2023 | -0.77 | -0.96 | 19.55% | 21.43% | - | - | ||
| Q3 2023 | -0.75 | -1.00 | 25.35% | 18.48% | - | - | ||
| Q2 2023 | -0.90 | -1.08 | 16.51% | -12.50% | - | - | ||
| Q1 2023 | -0.94 | -1.06 | 11.41% | -42.42% | - | - | ||
| Q4 2022 | -0.98 | -1.11 | 11.58% | -50.77% | - | - | ||
| Q3 2022 | -0.92 | -0.94 | 2.57% | -64.29% | - | - | ||
| Q2 2022 | -0.80 | -0.81 | 0.90% | -37.93% | - | - | ||
| Q1 2022 | -0.66 | -0.73 | 9.18% | -8.20% | - | - | ||
| Q4 2021 | -0.65 | -0.57 | -13.77% | -75.68% | 594.997K | -100.00% | -100.00% | |
| Q3 2021 | -0.56 | -0.62 | 9.75% | -7.69% | 874.283K | -100.00% | -100.00% | |
| Q2 2021 | -0.58 | -0.68 | 15.29% | -75.76% | 425.003K | -100.00% | -100.00% | |
| Q1 2021 | -0.61 | -0.61 | -0.01% | -45.24% | 1.224M | -100.00% | -100.00% | |
| Q4 2020 | -0.37 | -0.67 | 44.39% | - | 3.82M | 1.692M | 125.77% | - |
| Q3 2020 | -0.52 | -0.27 | -95.01% | - | 1.58M | 11.652M | -86.44% | - |
| Q2 2020 | -0.33 | -0.56 | 41.18% | - | 3.92M | 3.324M | 17.93% | - |
| Q1 2020 | -0.42 | -0.63 | 33.59% | - | 3.37M | 3.283M | 2.65% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
2
Average EPS beat (4)
-45.86%
Max EPS beat (4)
13.27%
Min EPS beat (4)
-106.51%
Revenue beat statistics
Revenue beat (4)
N/A
Average Revenue beat (4)
N/A
Max Revenue beat (4)
N/A
Min Revenue beat (4)
N/A
Analysis
In the last 4 quarters, KALV has beaten EPS estimates in 2 out of 4 releases
In the last 4 quarters, KALV reported -45.9% below the EPS estimates on average.
KALVISTA PHARMACEUTICALS INC / KALV Earnings FAQ
Can you provide the last earnings date for KALVISTA PHARMACEUTICALS INC?
KALVISTA PHARMACEUTICALS INC (KALV) last reported earnings on 1/8/2026.
Did KALV stock beat earnings estimates in the most recent quarter?
KALVISTA PHARMACEUTICALS INC (KALV) beat EPS estimates and beat revenue estimates in the most recent quarter.
How often does KALVISTA PHARMACEUTICALS INC (KALV) beat earnings estimates?
In the last 4 quarters, KALVISTA PHARMACEUTICALS INC (KALV) has beaten EPS estimates in 2 out of 4 releases.